DEA Issues Final Rule: Cannabis Officially Rescheduled to Schedule III
After two years of rulemaking, public comment, and legal challenges, the DEA has published its final rule moving cannabis from Schedule I to Schedule III — the most consequential federal cannabis policy change in 54 years.
Sarah Chen
Founder & Editor-in-Chief, Cannabis Dispensary
The Drug Enforcement Administration published its final rule rescheduling cannabis from Schedule I to Schedule III of the Controlled Substances Act on March 14, 2026, ending a rulemaking process that began with the Biden administration's HHS recommendation in 2023. The rule takes effect 30 days after publication in the Federal Register.
What the Final Rule Does
The final rule formally acknowledges that cannabis has a currently accepted medical use in the United States and that its abuse potential is substantially lower than Schedule I and II substances. The rule cites the FDA's 2023 scientific and medical evaluation, which reviewed over 250 peer-reviewed studies and concluded that cannabis meets the criteria for Schedule III classification.
The immediate practical consequence is the elimination of IRC Section 280E for cannabis businesses. The IRS confirmed in a concurrent guidance document that cannabis businesses may begin deducting ordinary and necessary business expenses for tax years beginning after the effective date. Industry analysts estimate this will reduce effective tax rates for licensed operators from an average of 65% to approximately 25–30% — comparable to other retail industries.
Research Implications
The rescheduling removes the most significant regulatory barrier to cannabis research. Under Schedule I, researchers required DEA Schedule I researcher registrations, institutional review board approval, and access to NIDA's limited cannabis supply. Schedule III classification allows researchers to use commercially available cannabis products in clinical trials, dramatically expanding the research pipeline. The NIH announced a $180 million cannabis research initiative concurrent with the final rule.
What Remains Unchanged
Cannabis remains a controlled substance under federal law. Possession, distribution, and cultivation without a DEA registration remain federal crimes. State-legal cannabis programs continue to operate under federal enforcement discretion rather than explicit federal authorization. Interstate commerce remains prohibited. The FDA has opened a docket to develop a regulatory framework for cannabis products, but has not yet issued guidance.
Industry Response
The cannabis industry responded with cautious optimism. The National Cannabis Industry Association called the rule "a historic step that validates what patients and the medical community have known for decades." Several multi-state operators reported that the 280E relief would allow them to reinvest in expansion, employee wages, and product quality. Banking access remains a priority legislative issue, with the SAFER Banking Act still pending Senate action.
Legal Challenges
Two anti-cannabis advocacy groups filed suit in the D.C. Circuit Court of Appeals seeking to vacate the final rule, arguing the DEA exceeded its statutory authority. Legal experts give these challenges low odds of success given the extensive administrative record supporting the rescheduling decision.